- Here for you, with care that understands
- Register Now for Life-Changing Care
Prof. Antoine Italiano, MD, PhD, is an expert medical oncologist, renowned for his significant contributions to early drug development in immuno-oncology, translational research and targeted therapies.
His groundbreaking work has advanced the understanding of immunotherapy’s therapeutic potential transforming patient outcomes. Collaborating with our teams, he has delved into GPCRs, a high-potential therapeutic target in immuno-oncology, providing valuable insights for our innovative therapies.
Prof. Italiano’s commitment to precision medicine has played a pivotal role in shaping Domain’s expertise in precision research, aiming to bridge clinical management gaps and expand therapeutic.
Prof. Italiano holds several key positions, including the Head of Early Phase Clinical Trials at Institut Bergonié, leading a team of over 80 experts responsible for the implementation of Phase I and basket studies across various solid tumor types and hematological malignancies in immuno-oncology. His leadership also extends to the Precision Medicine program at Gustave Roussy Institut, where Prof. Italiano contributes to the advancement of precision medicine in oncology.
His extensive research covers a range of early clinical development trials. As a principal investigator, he has overseen more than 50 Phase I trials across solid tumors, translating scientific insights into clinical practice. In the past 5 years, Prof. Italiano led over 40 Phase II and III trials. Prof. Italiano also contributes significantly to translational research, focusing on sensitivity and resistance to immunotherapies and targeted therapies, identifying predictive biomarkers that inform effective therapeutic decisions.
Prof. Italiano is invested in developing clinical research for rare tumors, particularly in pioneering sarcoma therapies. Working alongside a dedicated team of experts from the CONDOR project, which combines precision medicine and immunotherapy, he aims to improve the life expectancy of patients with metastatic sarcoma. He also coordinates the sarcoma research within the Multipli study, a cancer pilot project under the France Genomic Medicine 2025 plan, establishing one of the largest genomic testing programs in Europe.
Driven by the unmet needs in precision medicine, Prof. Italiano has dedicated his career to researching cancer cell biology, aiming to transform clinical management for patients. As a Professor of Medicine and Medical Oncology, he leads the Sarcotarget team within the Bordeaux Institute of Oncology (BRIC) project, endorsed by Inserm, uniting all current research efforts on cancers with poor prognosis and rare cancers.
An active member of esteemed organizations such as ASCO, ESMO and AACR, Prof Italiano holds a PhD in Molecular Aspects of Cell Biology and has completed a post-doctoral fellowship in Dr. Cristina Antonescu’s laboratory at the Memorial Sloan Kettering Cancer Center in New York.
Professor Antoine Italiano is the head of the Early Phase Trials and Sarcoma Units at Institut Bergonié, Bordeaux, France. He has been trained as a medical oncologist and obtained the Best Medical Thesis Price from Nice Medical School in 2005. He gained a PhD degree in Molecular Aspects of Cell Biology in 2008 and completed his training with a post-doctoral fellowship in the laboratory of Cristina Antonescu at Memorial Sloan Kettering Cancer Center, New York, USA.
His main research interests are in early clinical development, phase I trials across solid tumours, pharmacodynamic biomarkers, early phase II trials and sarcoma. He is also involved in translational research aspects related to sensitivity and resistance to targeted therapies, notably in soft-tissue sarcoma models.
He has been a Principal Investigator of more than 40 phase I trials during the past 5 years as well as a dozen phase II and phase III trials in sarcomas.
He is a member of ASCO, AACR, and ESMO.
He is a peer reviewer for several oncology journals and has contributed to over 200 peer-reviewed publications, including publications as first or last author in the Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.
Absolutely amazing, i have received a great support from Prof. Italiano.
